US20060094104A1 - Animal protein-free media for cultivation of cells - Google Patents

Animal protein-free media for cultivation of cells Download PDF

Info

Publication number
US20060094104A1
US20060094104A1 US10/976,399 US97639904A US2006094104A1 US 20060094104 A1 US20060094104 A1 US 20060094104A1 US 97639904 A US97639904 A US 97639904A US 2006094104 A1 US2006094104 A1 US 2006094104A1
Authority
US
United States
Prior art keywords
cells
protein
culture medium
virus
cultivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/976,399
Other languages
English (en)
Inventor
Leopold Grillberger
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060094104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US10/976,399 priority Critical patent/US20060094104A1/en
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRILLBERGER, LEOPOLD, REITER, MANFRED, DORNER, FRIEDRICH, MUNDT, WOLFGANG
Priority to DK10004393.4T priority patent/DK2213725T4/da
Priority to ES10004392T priority patent/ES2394746T3/es
Priority to PL10004395T priority patent/PL2213726T3/pl
Priority to SI200531584T priority patent/SI2218776T1/sl
Priority to CA 2585518 priority patent/CA2585518A1/fr
Priority to CN2005800367448A priority patent/CN101065480B/zh
Priority to FIEP10004393.4T priority patent/FI2213725T4/fi
Priority to EP20100004394 priority patent/EP2218776B1/fr
Priority to PT10004394T priority patent/PT2218776E/pt
Priority to SI200531583T priority patent/SI2213725T1/sl
Priority to RU2007119719A priority patent/RU2383616C2/ru
Priority to PT10004392T priority patent/PT2213724E/pt
Priority to EP10004393.4A priority patent/EP2213725B2/fr
Priority to PT10004395T priority patent/PT2213726E/pt
Priority to ES10004393T priority patent/ES2393317T3/es
Priority to JP2007538292A priority patent/JP4847962B2/ja
Priority to DK10004395T priority patent/DK2213726T3/da
Priority to ES10004394T priority patent/ES2393703T3/es
Priority to EP05798575A priority patent/EP1805298A1/fr
Priority to DK10004394T priority patent/DK2218776T3/da
Priority to DK10004392T priority patent/DK2213724T3/da
Priority to AU2005299040A priority patent/AU2005299040B2/en
Priority to PCT/EP2005/010973 priority patent/WO2006045438A1/fr
Priority to EP10004392.6A priority patent/EP2213724B2/fr
Priority to KR1020077011812A priority patent/KR101043547B1/ko
Priority to SI200531601T priority patent/SI2213724T1/sl
Priority to PL10004392T priority patent/PL2213724T3/pl
Priority to PL10004393.4T priority patent/PL2213725T5/pl
Priority to PL10004394T priority patent/PL2218776T3/pl
Priority to PT10004393T priority patent/PT2213725E/pt
Priority to MX2007005132A priority patent/MX2007005132A/es
Priority to SI200531640T priority patent/SI2213726T1/sl
Priority to EP20100004395 priority patent/EP2213726B1/fr
Priority to ES10004395T priority patent/ES2400214T3/es
Publication of US20060094104A1 publication Critical patent/US20060094104A1/en
Priority to US11/858,844 priority patent/US20080009040A1/en
Priority to US11/980,833 priority patent/US20080064105A1/en
Priority to US11/981,373 priority patent/US20080064080A1/en
Priority to US12/781,661 priority patent/US20110081722A1/en
Priority to US12/965,111 priority patent/US8440408B2/en
Priority to HK11101173A priority patent/HK1147110A1/xx
Priority to HK11101286A priority patent/HK1147284A1/xx
Priority to US13/864,118 priority patent/US8748156B2/en
Priority to US14/268,859 priority patent/US9222075B2/en
Priority to US14/954,705 priority patent/US9714411B2/en
Priority to US15/598,406 priority patent/US9809796B2/en
Priority to US15/712,408 priority patent/US10138461B2/en
Priority to US16/173,420 priority patent/US10655099B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components

Definitions

  • the present invention relates to animal protein-free cell culture media comprising a polyamine and a plant- and/or yeast-derived hydrolysate.
  • the invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
  • FCS fetal calf serum
  • serum or serum-derived substances such as albumin, transferrin or insulin
  • human serum derived additives have to be tested for all known viruses, including hepatitis and HIV, that can be transmitted by serum.
  • bovine serum and products derived therefrom bear the risk of BSE contamination.
  • all serum-derived products can be contaminated by unknown constituents.
  • problems e.g. the varying quality in composition of the different batches and the risk of contamination with mycoplasma, viruses or BSE), particularly if the cells are used for production of drugs or vaccines for human administration.
  • Simple serum free medium typically includes basal medium, vitamins, amino acids organic or inorganic salts, and optionally additional components to make the medium nutritionally complex.
  • Soy hydrolysates are known to be useful for fermentation processes and can enhance the growth of many fastidious organisms, yeasts and fungi.
  • WO 96/26266 describes that papaic digests of soy meal are a source of carbohydrate and nitrogen and many of the components can be used in tissue culture.
  • Franek et al. (Biotechnology Progress (2000) 16, 688-692) describe growth and productivity promoting effects of defined soy hydrolysate peptide fractions.
  • WO 96/15231 discloses serum-free medium composed of the synthetic minimal essential medium and yeast extract for propagation of vertebrate cells and virus production process.
  • a medium formulation composed of a basal cell culture medium comprising a rice peptide and an extract of yeast and enzymatic digest thereof, and/or a plant lipid for growth of animal cells is disclosed in WO 98/15614.
  • a medium comprising purified soy hydrolysate for the cultivation of recombinant cells is disclosed in WO 01/23527.
  • WO 00/03000 discloses a medium that comprises a soy hydrolysate and a yeast extract, but also requires the presence of recombinant forms of animal proteins, such as growth factors.
  • EP-A-0 481 791 describes a biochemically defined culture medium for culturing engineered CHO cells, which is free from protein, lipid and carbohydrate isolated from an animal source, further comprising a recombinant insulin or insulin analogue, 1% to 0.025% w/v papain digested soy peptone and putrescine.
  • WO 98/08934 describes a serum-free eukaryotic cell culture comprising hydrolyzed soy peptides (1-1000 mg/L), 0.01 to 1 mg/L putrescine and a variety of animal-derived components, including albumin, fetuin, various hormones and other proteins.
  • putrescine is also known to be contained in standard media like DMEM/Ham's F12 in a concentration of 0.08 mg/L.
  • the media known in the state of art are often nutritionally insufficient and/or must be supplemented with animal-derived protein supplements or recombinant versions of proteins, such as insulin, insulin like growth factor or other growth factors.
  • soy peptone extracts also designated as “soy hydrolysates”
  • soy hydrolysates On the basis of soy peptone extracts (also designated as “soy hydrolysates”) media have been developed, which do not contain animal proteins.
  • soy hydrolysates the quality of commercially available lots of soy hydrolysates varies extremely and as a result, there are large variations in the production of recombinant proteins or viral products (a variation of up to a factor of 3) as a function of the lots of soy hydrolysates used (“lot-to-lot variation”). This draw back affects the proliferation of the cells as well as the protein expression of each cell.
  • An object of the present invention is to provide an animal protein-free cell culture medium which does not contain any added supplementary proteins derived from an animal source and/or recombinant animal proteins, which allows efficient cell growth and in particular protein production in a continuous quality with respect to the amount of expression per cell.
  • a further object of the present invention is to provide a method for cultivating cells and a method for efficient expression of recombinant proteins which are free of animal proteins.
  • Another object of the present invention is to reduce plant and/or yeast derived hydrolysate in order to overcome inhibitory effects which would negatively impact the production yield of a desired recombinant or viral product. Hydrolysates were surprisingly found to be the cause of the lot-to-lot variations in production.
  • the animal protein-free cell culture medium according to the invention comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate, wherein the polyamine preferably originates from a source other than the protein hydrolysate.
  • the addition of at least one polyamine, in particular the addition of putrescine, to the animal protein-free cell culture medium provides the advantageous effect not only to promote the cell growth but in particular to increase the protein expression per cell and, in particular, recombinant protein expression per cell.
  • the animal protein-free medium according to the present invention allows consistent cell growth and increased yield of desired products, particularly of target proteins such as recombinant proteins, independent of the quality or lot variations of the protein hydrolysate, in particular of the vegetable hydrolysates, in the animal protein-free cell culture medium.
  • the specific supplementation of cell culture media with polyamines and a plant- and/or yeast-derived hydrolysate acts synergistically to increase cell growth, cell specific productivity and final cell density.
  • the animal protein free medium according to the present invention is more favorable for recombinant protein expression and cell growth rate compared to the media known in the art. Furthermore, the animal protein-free medium according to the present invention allows the reduction of the amount of protein hydrolysate to be added to a given volume of the cell culture medium.
  • FIG. 2 shows a table which compares the volumetric FVIII-CoA productivity of GD8/6 cells grown in media with different soy hydrolysate concentrations.
  • FIG. 3 shows a graph which compares the volumetric FVIII-CoA productivity of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 4 shows a graph which compares the specific growth rates of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 5 shows a table which compares the volumetric FVIII-CoA productivity (QP [U/L/D]) and the specific growth rate ( ⁇ [d ⁇ 1]) of GD8/6 cells and their standard deviation grown in media with 5 different selected lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.4% (w/v) or 0.25% (w/v)) with the same soy hydrolysates (0.25% (w/v)) with and without putrescine.2HCl at 1 mg/L.
  • QP [U/L/D] volumetric FVIII-CoA productivity
  • ⁇ [d ⁇ 1] specific growth rate
  • FIG. 6 shows a table which describes the average putrescine concentrations found in soy hydrolysates (0.4% (w/v) in cell culture medium) from different manufacturers.
  • FIG. 7 shows a table which compares the effect of soy hydrolysate (0.4% (w/v)) and soy hydrolysate (0.25% (w/v))+1,8 mg/L putrescine.2HCl on the volumetric productivity (QP expressed in [mg IgG1/L reactor volume/day] and cell specific productivity (qp [ ⁇ g IgG1/10E06 Cells/d]) in ARH77 cells secreting a monoclonal antibody.
  • QP expressed in [mg IgG1/L reactor volume/day]
  • cell specific productivity qp [ ⁇ g IgG1/10E06 Cells/d]
  • FIG. 8 shows a graph which compares the effect of soy hydrolysate (0.25% (w/v)) and soy hydrolysate (0.25% (w/v))+1 mg/L putrescine (1,8 mg/L putrescine.2HCl) on the cell specific erythropoeitin (EPO)-productivity of recombinant BHK cells (EPO production (Units)/glucose consumption (g).
  • EPO erythropoeitin
  • FIG. 9 shows a table comparing the effect of putrescine, omithine and spermine over a wider concentration range (0-18 mg/L) on the specific growth ( ⁇ absolute, ⁇ relative) and the cell specific productivity (Qp absolute, Qp relative) of GD8/6 cells cultivated in BAV-medium containing 0.0% soy hydrolysate and no amines, or BAV-medium containing a reduced soy hydrolysate concentration of 0.25% supplemented with polyamines in the concentration range indicated above.
  • One aspect of the invention relates to an animal protein-free cell culture medium comprising at least one polyamine and a plant- and/or yeast-derived hydrolysate, in a concentration sufficiently reduced in order to avoid potential inhibitory effects of the hydrolysate.
  • polyamine refers to any of a group of organic compounds composed of carbon, nitrogen, and hydrogen, and containing two or more amino groups.
  • the term encompasses molecules selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, and ornithine.
  • the concentration of the polyamine is present in a concentration ranging from about 0.5 mg/L to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium.
  • the total concentration of the plant- and/or yeast-derived protein hydrolysate in the animal protein-free cell culture medium is about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v); i.e. if the medium contains a plant- and a yeast derived protein hydrolysate, the total concentration is calculated by the summing up the concentration values of each of the protein hydrolysate components contained in the medium.
  • animal protein free cell culture medium refers to a medium that does not contain proteins and/or protein components from higher multicellular non-plant eukaryotes. Typical proteins that are avoided are those found in serum and serum-derived substances, such as albumin, transferrin, insulin and other growth factors.
  • the animal protein free cell culture medium is also free of any purified animal derived products and recombinant animal derived products as well as protein digests and extracts thereof or lipid extracts or purified components thereof.
  • Animal proteins and protein components are to be distinguished from non-animal proteins, small peptides and oligopeptides obtainable from plants (usually 10-30 amino acids in length), such as soy bean, and lower eukaryotes, such as yeast which may be included into the animal protein free cell culture medium according to the invention.
  • the animal protein free culture medium according to the invention may be based on any basal medium such as DMEM, Ham's F12, Medium 199, McCoy or RPMI generally known to the skilled worker.
  • the basal medium may comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, and sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell which is generally known to the person skilled in the art.
  • the medium may contain auxiliary substances, such as buffer substances like sodium bicarbonate, antioxydants, stabilisers to counteract mechanical stress, or protease inhibitors.
  • a non-ionic surfactant such as mixtures of polyethylene glycols and polypropylene glycols (e.g. Pluronic F68®, SERVA) can be added as a defoaming agent.
  • the polyamine employed for the animal protein free culture medium according to the invention may be selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, ornithine, and combinations thereof. Most preferably, the animal protein free culture medium contains ornithine, putrescine and spermine.
  • the polyamine controls DNA- and RNA-synthesis, cell proliferation, cell differentiation, membrane stabilization, and/or antioxidative DNA-protection.
  • Putrescine, spermidine, spermine, and ornithine are examples of polyamines which exhibit these functions.
  • Another example of a polyamine is cadaverine.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the polyamine is present in a concentration ranging from about 0.5 to about. 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium, and the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • the plant-derived protein hydrolysate used for the animal protein-free cell culture medium according to the invention is preferably selected from the group consisting of a cereal hydrolysate and/or a soy hydrolysate.
  • the soy hydrolysate may be a highly purified soy hydrolysate, a purified soy hydrolysate or crude soy hydrolysate.
  • hydrolysate includes any enzymatic digest of a vegetable or yeast extract.
  • the “hydrolysate” can be further enzymatically digested, for example by papain, and/or formed by autolysis, thermolysis and/or plasmolysis.
  • Hydrolysates to be used according to the present invention are also commercially available, such as HyPep 1510®, Hy-Soy®, Hy-Yeast 412® and Hi-Yeast 444®, from sources such as Quest International, Norwich, N.Y., OrganoTechnie, S.A. France, Irish Hefewerke GmbH, Germany, or DMV Intl. Delhi, N.Y.
  • Sources of yeast extracts and soy hydrolysates are also disclosed in WO 98/15614, WO 00/03000, WO 01/23527 and U.S. Pat. No. 5,741,705.
  • the hydrolysates are preferably purified from crude fraction, because impurities could interfere with efficient cultivation. Purification can be carried out by ultrafiltration or Sephadex chromatography, for example with Sephadex 25 or Sephadex G10 or equivalent materials, ion exchange chromatography, affinity chromatography, size exclusion chromatography or reverse-phase-chromatography.
  • the fractions may contain hydrolysates of defined molecular weight, preferably up to about 1000 Dalton, more preferably up to about 500 Dalton, most preferably up to about 350 Dalton. At least about 90% of the hydrolysate has preferably a molecular weight of up to about 1000 Dalton.
  • the average molecular weight of the hydrolysates lies preferably between about 220 and about 375 Daltons.
  • the pH value of the hydrolysate should be in the range of from about 6.5 to about 7.5.
  • the total nitrogen content is preferably between about 5 and about 15%, and the ash content is preferably up to about 20%.
  • the free amino acid content is preferably between about 5% and about 30%.
  • the endotoxin content is preferably less than about 500 U/g.
  • the invention also provides a method of using at least one polyamine for addition to an animal protein-free cell culture medium containing a plant- and/or yeast-derived protein hydrolysate, for increasing the protein expression yield in the cultured cells.
  • the polyamine is present in the culture medium in a total concentration ranging from about 0.5 to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium.
  • the polyamine is selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, ornithine, and combinations thereof.
  • the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • the present invention further relates to a method for cultivating cells, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the present invention is not limited to any type of cells.
  • the cells used are for example mammalian cells, insect cells, avian cells, bacterial cells, yeast cells.
  • the cells may be for example stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products.
  • the cells may also be for example cells producing a protein of interest without recombinant transformation, e.g. a B-cell producing an antibody, which may be transformed into an immortalized status e.g. by viral infection like Epstein Barr Virus infection.
  • the cells may also be for example primary cells, e.g. chicken embryo cells, or primary cell lines. Preferred are cells that are used for in vitro virus production.
  • the cells may be BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, and chicken embryo cells.
  • the cells used according to the present invention may be cultivated by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostate-cultivation all of which are generally known in the field.
  • the present invention further relates to a method for expressing a target protein such as a heterologous or autologous protein or a recombinant protein, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the nucleic acid sequence comprising a sequence coding for the target protein may be a vector.
  • the vector may be a virus or a plasmid.
  • the sequence coding for a target protein may be a specific gene or a biological functional part thereof.
  • the target protein is at least a biologically active part of a blood coagulation factor such as the Factor VIII or at least a biologically active part of a protein involved in the production of red blood cells and angiogenesis such as erythropoeitin, or a monoclonal antibody.
  • the nucleic acid further comprises other sequences suitable for controlled expression of a target protein such as promotor sequences, as enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to the person skilled in the art.
  • promotor sequences as enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to the person skilled in the art.
  • CHO cells for the production of recombinant coagulation factor VIII
  • BHK cells for the production of recombinant erythropoietin
  • Epstein Barr virus transformed immortalized human B cells for the production of human antibodies.
  • the present invention further relates to a method for producing a virus or part of a virus, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate. More preferably, the polyamine originates from a source other than the protein hydrolysate.
  • the virus used in the method according to the invention may be any pathogenic virus, mammalian, preferably human virus, such as a vaccinia or attenuated vaccinia virus, e.g. for smallpox vaccines, coronavirus, preferably SARS virus, e.g. for production of SARS vaccines, orthomyoxyvirus, preferably influenza virus, e.g. for production of influenza vaccines, paramyxovirus, retrovirus, influenza A or B virus, Ross River virus, flavivirus, preferably West Nile virus or FSME virus (i.e. tick borne encephalitis virus), e.g. for the production of the respective vaccines, picornavirus, arena virus, herpesvirus, poxvirus or adenovirus.
  • a vaccinia or attenuated vaccinia virus e.g. for smallpox vaccines, coronavirus, preferably SARS virus, e.g. for production of SARS vaccines, orthomyoxyvirus, preferably influenza virus
  • the virus may be a wild-type-virus, an attenuated virus, a reassortant virus, or a recombinant virus or combinations thereof, e.g. attenuated and recombinant.
  • an infectious nucleic acid clone may be used instead of actual virions being used to infect cells with a virus.
  • Split virions may also be used instead of actual virions being used to infect cells with a virus.
  • the method for expressing a protein or producing a virus may be used for producing immunogenic compositions comprising a virus or a virus antigen.
  • the cells used for the method for producing a virus may be selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
  • the cells are cultivated by a method selected from the group consisting of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostat-cultivation.
  • Preferred combinations of cells with viruses for producing a virus or part of a virus are Vero cell/attenuated vaccinia, Vero cell/Vaccinia, Vero cell/Hepatitis A, Vero cell/Influenza Virus, Vero cell/West Nile Virus, Vero cell/SARS Virus, chicken embryo cells/FSME virus.
  • the present invention further relates to a method of using the animal protein-free cell culture medium according to the invention for culturing cells expressing a target protein.
  • Animal protein free medium was prepared with basal DMEM/HAM's F12 (1:1) medium supplemented with inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were L-glutamine (600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic® (SERVA) (0.25 g/L), sodium selenite (50 nM). Additionally, essential amino acids were supplemented to the cell culture medium. Further, varying concentrations of soy hydrolysate (Quest Technologies, NY or DMV Intl., NY ) in the range of 0.0-1.0% and varying concentrations of polyamines (0-10 mg/L) were added ( FIG. 1-9 )
  • Cell cultures of recombinant mammalian cells were grown in suspension in a chemostat culture in 10 I bioreactors.
  • the culture conditions of 37° C., oxygen saturation 20% and pH 7.0 to 7.1 were kept constant.
  • the cultures were supplied with a constant feed of BAV-medium as defined in Example 1 additionally supplemented with soy hydrolysates in the range of 0.1-1.0% and/or addition of putrescine.2HCl in the range of 0-1 mg/L (cf. FIG. 1-5 ).
  • Factor VIII Factor VIII
  • FIGS. 1 to 5 and 9 The activity of Factor VIII (FVIII) was measured by a chromogenic assay (Chromogenic, Sweden).
  • the volumetric productivity is calculated from the amount of activity units or antigen titers yielded per liter reactor volume per day (U/L/d or mg/L/d) in the respective production systems.
  • the cell specific productivity is defined as the specific amount of produced protein (U or ⁇ g) per number of cells per day (cf. FIGS. 7 and 9 ) or as the specific amount of produced protein (U) produced per amount of D-glucose consumed by the cells (cf. FIG. 8 ).
  • GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of different soy hydrolysate lots.
  • the volumetric FVIII-productivity varied from about 600 to 1800 U/L/d and the specific growth rates varied of from 0.35 to 0.52 ⁇ [d ⁇ 1] between the different lots (cf. FIG. 1 ). This indicates that the soy hydrolysate lots at the 0.4% concentration does not allow consistent growth of the GD8/6 cells, possibly due to inhibitory substances affecting the specific growth rate ( ⁇ ) which are contained in the soy hydrolysates.
  • GD8/6 cells were supplied with BAV-medium containing different concentrations of soy hydrolysate lot M022257 (in the range of 0.15-1.0% w/v).
  • the volumetric FVIII-productivity varied of from 500 to 1.100 U/L/d and reached an optimum productivity of 1.100 U/L/d at a soy hydrolysate concentration of 0.4% (w/v) (cf. FIG. 2 ).
  • GD8/6 cells were supplied with BAV-medium containing 0.25% (w/v) of the same 5 different soy hydrolysate lots as described in Example 5 ( FIGS. 3A and 4A ) and 0.25% (w/v) soy hydrolysate of the same soy hydrolysate lots additionally supplemented with 1 mg/L putrescine.2 HCl ( FIGS. 3B and 4B ), respectively.
  • the volumetric FVIII-productivity varied of from 1700 U/L/d to 500 U/L/d in the cells grown BAV-SP medium containing 0.25% (w/v) soy hydrolysate of different soy hydrolysate lots ( FIG. 3A ).
  • the specific growth rate varied of from 0.58 to 0.24 ⁇ [d ⁇ 1], indicating that the reduction of the soy hydrolysate concentration does not lead to an improved or more consistent growth rate of the cells ( FIG. 4A ).
  • putrescine to animal protein-free cell culture media not only promotes protein expression rate of cultured cells but it also reduces the amount of plant hydrolysate to be included into the culture media in order to obtain the same cell growth.
  • culture media become less affected by the lot-by-lot variation of quality of plant hydrolysate and thus an overall improvement of the cell culture conditions is achieved.
  • FIG. 5 comprises the statistical analysis of the Examples shown in FIG. 1, 2 and 4 : GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate and 1 mg/L putrescine.2HCl. Standard deviations are calculated based on five selected lots of soy hydrolysates (K119-1, K138-1, M022963, M024423, M022453).
  • volumetric and cell specific FVIII-productivity and the specific growth rate with 0.25% (w/v) soy hydrolysate was lower than with 0.4% (w/v) soy hydrolysate, which confirms the optimum depicted in FIG. 2 .
  • the volumetric and cell specific FVIII-productivity and the specific growth rate increases in cell culture medium containing 0.25% (w/v) soy hydrolysate+1 mg/L putrescine.2HCl.
  • Examples 7 and 8 show that putrescine is an active compound supporting cell growth and, more specifically protein expression. Therefore, the concentration of putrescine from different soy hydrolysate lots from 2 different suppliers (Quest and DMV) were quantitatively analysed by a HPLC method and evaluated statistically. The concentration in the cell culture media prepared with soy hydrolysate from both suppliers was approximately 2.3 mg/L putrescine, when soy hydrolysate was added to the medium in a concentration of 0.4% (w/v) (cf. FIG. 6 ).
  • ARH77 cells human lymphoblastoid cell line stably expressing hlgG
  • BAV medium 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl.
  • Arithmetic means and standard deviations were calculated from data points representing the steady states for the respective medium formulations.
  • the volumetric hlgG-volumetric productivity/cell specific productivity in BAV-medium supplemented with 0.4% (w/v) soy hydrolysate was lower than in BAV-medium supplemented with 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl.
  • This experiment indicates that the medium composition according to the present invention is capable to promote also the expression of monoclonal antibodies from a transformed cell line. Further, the specific medium composition can also be used in perfusion cultures (cf. FIG. 7 ).
  • Recombinant BHK cells were grown to confluence in 5% (v/v) fetal calf serum containing medium. The cells were washed with protein-free medium and incubated for 3 days in BAV medium supplemented with 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl ( FIG. 8 ). Since no cell counting in this experiment was performed, the glucose consumption rate (g/L) was measured over three days to prove equivalent biomass in the culture system. The EPO-activity (mU/ml) was correlated with the glucose consumption rate (g/L) over three days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
US10/976,399 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells Abandoned US20060094104A1 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
US10/976,399 US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells
DK10004393.4T DK2213725T4 (da) 2004-10-29 2005-10-12 Medium frit for dyreprotein til dyrkning af celler
ES10004392T ES2394746T3 (es) 2004-10-29 2005-10-12 Medio exento de proteínas animales para el cultivo de células
PL10004395T PL2213726T3 (pl) 2004-10-29 2005-10-12 Wolne od białek zwierzęcych pożywki do hodowli komórek
SI200531584T SI2218776T1 (sl) 2004-10-29 2005-10-12 Mediji brez Ĺľivalskih proteinov za kultiviranje celic
CA 2585518 CA2585518A1 (fr) 2004-10-29 2005-10-12 Milieux de culture de cellules exempts de proteine animale
CN2005800367448A CN101065480B (zh) 2004-10-29 2005-10-12 用于细胞培养的无动物蛋白培养基
FIEP10004393.4T FI2213725T4 (fi) 2004-10-29 2005-10-12 Eläinproteiinia sisältämätön elatusaine solujen viljelyä varten
EP20100004394 EP2218776B1 (fr) 2004-10-29 2005-10-12 Milieu exempt de protéines animales pour la culture de cellules
PT10004394T PT2218776E (pt) 2004-10-29 2005-10-12 Meios sem proteína animal para cultivo de células
SI200531583T SI2213725T1 (sl) 2004-10-29 2005-10-12 Mediji brez Ĺľivalskih proteinov za kultiviranje celic
RU2007119719A RU2383616C2 (ru) 2004-10-29 2005-10-12 Не содержащая животных белков среда для культивирования клеток
PT10004392T PT2213724E (pt) 2004-10-29 2005-10-12 Meios sem proteínas animais para a cultura de células
EP10004393.4A EP2213725B2 (fr) 2004-10-29 2005-10-12 Milieu exempt de proteines animales pour la culture de cellules
PT10004395T PT2213726E (pt) 2004-10-29 2005-10-12 Meios sem proteína animal para cultivo de células
ES10004393T ES2393317T3 (es) 2004-10-29 2005-10-12 Medio exento de proteínas animales para el cultivo de células
JP2007538292A JP4847962B2 (ja) 2004-10-29 2005-10-12 動物タンパク質を含まない細胞培養培地
DK10004395T DK2213726T3 (da) 2004-10-29 2005-10-12 Medium frit for dyreprotein til dyrkning af celler
ES10004394T ES2393703T3 (es) 2004-10-29 2005-10-12 Medio exento de proteínas animales para el cultivo de células
EP05798575A EP1805298A1 (fr) 2004-10-29 2005-10-12 Milieux de culture de cellules exempts de proteine animale
DK10004394T DK2218776T3 (da) 2004-10-29 2005-10-12 Dyreproteinfrit celledyrkningsmedie til dyrkning af celler
DK10004392T DK2213724T3 (da) 2004-10-29 2005-10-12 Medium frit for dyreprotein til dyrkning af celler
AU2005299040A AU2005299040B2 (en) 2004-10-29 2005-10-12 Animal protein-free media for cultivation of cells
PCT/EP2005/010973 WO2006045438A1 (fr) 2004-10-29 2005-10-12 Milieux de culture de cellules exempts de proteine animale
EP10004392.6A EP2213724B2 (fr) 2004-10-29 2005-10-12 Milieu exempt de proteines animales pour la culture de cellules
KR1020077011812A KR101043547B1 (ko) 2004-10-29 2005-10-12 세포 배양용의 동물성 단백질이 없는 배지
SI200531601T SI2213724T1 (sl) 2004-10-29 2005-10-12 Mediji brez živalskih proteinov za kultiviranje celic
PL10004392T PL2213724T3 (pl) 2004-10-29 2005-10-12 Wolne od białek zwierzęcych pożywki do hodowli komórek
PL10004393.4T PL2213725T5 (pl) 2004-10-29 2005-10-12 Wolne od białek zwierzęcych pożywki do hodowli komórek
PL10004394T PL2218776T3 (pl) 2004-10-29 2005-10-12 Wolne od białek zwierzęcych pożywki do hodowli komórek
PT10004393T PT2213725E (pt) 2004-10-29 2005-10-12 Meios sem proteína animal para cultivo de células
MX2007005132A MX2007005132A (es) 2004-10-29 2005-10-12 Medios libres de proteina animal para cultivo de celulas.
SI200531640T SI2213726T1 (sl) 2004-10-29 2005-10-12 Mediji brez Ĺľivalskih proteinov za kultiviranje celic
EP20100004395 EP2213726B1 (fr) 2004-10-29 2005-10-12 Milieu exempt de proteines animales pour la culture de cellules
ES10004395T ES2400214T3 (es) 2004-10-29 2005-10-12 Medio exento de proteínas animales para el cultivo de células
US11/858,844 US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells
US11/980,833 US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US11/981,373 US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells
US12/965,111 US8440408B2 (en) 2004-10-29 2010-12-10 Animal protein-free media for cultivation of cells
HK11101173A HK1147110A1 (en) 2004-10-29 2011-02-07 Animal protein-free media for cultivation of cells
HK11101286A HK1147284A1 (en) 2004-10-29 2011-02-10 Animal protein-free media for cultivation of cells
US13/864,118 US8748156B2 (en) 2004-10-29 2013-04-16 Animal protein-free media for cultivation of cells
US14/268,859 US9222075B2 (en) 2004-10-29 2014-05-02 Animal protein-free media for cultivation of cells
US14/954,705 US9714411B2 (en) 2004-10-29 2015-11-30 Animal protein-free media for cultivation of cells
US15/598,406 US9809796B2 (en) 2004-10-29 2017-05-18 Animal protein-free media for cultivation of cells
US15/712,408 US10138461B2 (en) 2004-10-29 2017-09-22 Animal protein-free media for cultivation of cells
US16/173,420 US10655099B2 (en) 2004-10-29 2018-10-29 Animal protein-free media for cultivation of cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/976,399 US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/858,844 Division US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells
US11/981,373 Division US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US11/980,833 Division US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 Continuation US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells

Publications (1)

Publication Number Publication Date
US20060094104A1 true US20060094104A1 (en) 2006-05-04

Family

ID=35447241

Family Applications (12)

Application Number Title Priority Date Filing Date
US10/976,399 Abandoned US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells
US11/858,844 Abandoned US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells
US11/980,833 Abandoned US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US11/981,373 Abandoned US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 Abandoned US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells
US12/965,111 Active US8440408B2 (en) 2004-10-29 2010-12-10 Animal protein-free media for cultivation of cells
US13/864,118 Active US8748156B2 (en) 2004-10-29 2013-04-16 Animal protein-free media for cultivation of cells
US14/268,859 Active US9222075B2 (en) 2004-10-29 2014-05-02 Animal protein-free media for cultivation of cells
US14/954,705 Active US9714411B2 (en) 2004-10-29 2015-11-30 Animal protein-free media for cultivation of cells
US15/598,406 Active US9809796B2 (en) 2004-10-29 2017-05-18 Animal protein-free media for cultivation of cells
US15/712,408 Active US10138461B2 (en) 2004-10-29 2017-09-22 Animal protein-free media for cultivation of cells
US16/173,420 Active US10655099B2 (en) 2004-10-29 2018-10-29 Animal protein-free media for cultivation of cells

Family Applications After (11)

Application Number Title Priority Date Filing Date
US11/858,844 Abandoned US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells
US11/980,833 Abandoned US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US11/981,373 Abandoned US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 Abandoned US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells
US12/965,111 Active US8440408B2 (en) 2004-10-29 2010-12-10 Animal protein-free media for cultivation of cells
US13/864,118 Active US8748156B2 (en) 2004-10-29 2013-04-16 Animal protein-free media for cultivation of cells
US14/268,859 Active US9222075B2 (en) 2004-10-29 2014-05-02 Animal protein-free media for cultivation of cells
US14/954,705 Active US9714411B2 (en) 2004-10-29 2015-11-30 Animal protein-free media for cultivation of cells
US15/598,406 Active US9809796B2 (en) 2004-10-29 2017-05-18 Animal protein-free media for cultivation of cells
US15/712,408 Active US10138461B2 (en) 2004-10-29 2017-09-22 Animal protein-free media for cultivation of cells
US16/173,420 Active US10655099B2 (en) 2004-10-29 2018-10-29 Animal protein-free media for cultivation of cells

Country Status (17)

Country Link
US (12) US20060094104A1 (fr)
EP (5) EP2218776B1 (fr)
JP (1) JP4847962B2 (fr)
KR (1) KR101043547B1 (fr)
CN (1) CN101065480B (fr)
AU (1) AU2005299040B2 (fr)
CA (1) CA2585518A1 (fr)
DK (4) DK2218776T3 (fr)
ES (4) ES2400214T3 (fr)
FI (1) FI2213725T4 (fr)
HK (2) HK1147110A1 (fr)
MX (1) MX2007005132A (fr)
PL (4) PL2218776T3 (fr)
PT (4) PT2213725E (fr)
RU (1) RU2383616C2 (fr)
SI (3) SI2213725T1 (fr)
WO (1) WO2006045438A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132195A1 (fr) * 2008-04-23 2009-10-29 Michigan State University Lignée cellulaire aviaire immortelle et procédés d’utilisation
US20100008953A1 (en) * 2006-06-20 2010-01-14 Daniel Malarme Process for producing poxviruses and poxvirus compositions
US20100120093A1 (en) * 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US20100285533A1 (en) * 2008-01-09 2010-11-11 Krueger Olaf Culture media additive and process for using it
US20110053224A1 (en) * 2008-01-25 2011-03-03 Yangming Martin Lo Novel composition of matter and method for stimulating the growth of beneficial microorganisms
US9441207B2 (en) 2008-06-16 2016-09-13 Intervet Inc. Method of replicating viruses in suspension cultures of dog kidney cells
WO2019010497A1 (fr) 2017-07-07 2019-01-10 Baxalta Incorporated Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombiné
WO2019010496A1 (fr) 2017-07-07 2019-01-10 Baxalta Incorporated Traitement de patients atteints d'une forme grave de la maladie de von willebrand subissant une intervention chirurgicale non urgente par l'administration de vwf recombiné
CN109790521A (zh) * 2016-09-21 2019-05-21 德国癌症研究中心 在基本上无血清的培养基中大规模产生细小病毒h-1的优化的方法
WO2019183290A1 (fr) 2018-03-21 2019-09-26 Baxalta Incorporated Séparation de vwf et de propeptide de vwf par des procédés chromatographiques
CN110914293A (zh) * 2017-07-06 2020-03-24 里珍纳龙药品有限公司 用于制备糖蛋白的细胞培养工艺
WO2020160460A1 (fr) 2019-02-01 2020-08-06 Baxalta Incorporated Procédés de traitement prophylactique utilisant vwf recombinant (rvwf)
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
WO2021158777A1 (fr) 2020-02-04 2021-08-12 Baxalta Incorporated Traitement de la ménorragie chez des patients atteints de maladie de von willebrand sévère par administration de vwf recombinant
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DK2522717T3 (da) * 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
MX2009002748A (es) 2006-09-13 2009-03-26 Abbott Lab Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
JPWO2008047596A1 (ja) * 2006-10-18 2010-02-25 不二製油株式会社 冷凍耐性ある酵母
US8821480B2 (en) * 2008-07-16 2014-09-02 Intuitive Surgical Operations, Inc. Four-cable wrist with solid surface cable channels
CA2735404C (fr) * 2008-08-28 2013-04-16 Novartis Ag Production de squalene a partir de levures hyperproductrices
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
CA2751021A1 (fr) 2008-12-30 2010-07-08 Baxter International Inc. Methode d'amplification de la croissance cellulaire avec un alkyl-amine-n-oxyde (annox)
CN101851608B (zh) * 2009-03-31 2012-09-05 北京清大天一科技有限公司 一种悬浮培养bhk21细胞生产狂犬病病毒的方法
IN2012DN00801A (fr) 2009-07-31 2015-06-26 Baxter Int
ES2948612T3 (es) 2009-09-21 2023-09-14 Takeda Pharmaceuticals Co Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas
KR102007773B1 (ko) 2010-07-08 2019-08-06 박스알타 인코퍼레이티드 세포 배양에서 재조합 고분자량 ｖＷＦ를 생산하는 방법
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
KR102222864B1 (ko) 2010-10-27 2021-03-04 박스알타 인코퍼레이티드 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드
CN102127525B (zh) * 2010-12-27 2013-06-05 吉林亚泰生物药业股份有限公司 流感病毒疫苗株在Vero细胞上的适应方法
EP2778221B1 (fr) * 2011-02-07 2017-07-26 Life Technologies Corporation Compositions et procédés de stabilisation de composés sensibles
WO2012149197A2 (fr) 2011-04-27 2012-11-01 Abbott Laboratories Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2717905B1 (fr) 2011-06-10 2018-05-23 Baxalta GmbH Traitement d'une maladie de la coagulation par l'administration du fvw recombinant
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (fr) 2012-09-02 2014-03-06 Abbvie Inc. Procedes de controle de l'heterogeneite des proteines
ES2633960T3 (es) 2012-10-15 2017-09-26 Bristol-Myers Squibb Company Procesos de cultivo de células de mamífero para la producción de proteínas
EP2830651A4 (fr) 2013-03-12 2015-09-02 Abbvie Inc Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015101510A1 (fr) 2013-12-30 2015-07-09 Baxter Healthcare Sa Procédé de prédiction de caractéristique de performance d'hydrolysat de plante ou de levure et son utilisation
CN106282090B (zh) * 2015-06-08 2021-07-13 齐鲁制药有限公司 一种驯化后的cho-s细胞系及其培养方法与应用
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
JP6258536B1 (ja) 2017-03-03 2018-01-10 協和発酵キリン株式会社 ダルベポエチン組成物の製造方法およびダルべポエチン産生細胞の培養方法
ES2914987T3 (es) 2018-04-20 2022-06-20 Janssen Biotech Inc Calificación de columnas de cromatografía en métodos de fabricación para producir composiciones de anticuerpos anti-IL12/IL23
TW202039849A (zh) 2018-11-13 2020-11-01 美商健生生物科技公司 在產生抗cd38抗體之期間微量金屬的控制
EP3938390A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP2022525145A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
EP4028046B1 (fr) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Méthodes de traitement liés à des complexes du facteur de von willebrand et du complément c1q
CZ308590B6 (cs) * 2019-09-25 2020-12-16 Výzkumný ústav mlékárenský s.r.o. Hypoalergenní veganské médium pro kultivaci bakterií mléčného kvašení
JP2022552052A (ja) 2019-12-06 2022-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
BR112022019817A2 (pt) 2020-04-02 2022-12-06 Takeda Pharmaceuticals Co Variante de adamts13, composições e usos das mesmas
EP4043551A1 (fr) 2021-02-12 2022-08-17 Bühler AG Milieux nutritifs pour culture cellulaire contenant des hydrolysats de protéines végétales
KR102392018B1 (ko) * 2021-05-24 2022-04-27 한국해양과학기술원 스피룰리나 가수분해물을 포함하는 세포 배양용 배지 조성물 및 이의 제조방법
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
US20230287043A1 (en) 2022-03-02 2023-09-14 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production
WO2024039216A1 (fr) * 2022-08-19 2024-02-22 셀미트주식회사 Procédé de culture de cellules animales ou d'une lignée de cellules animales

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431629A (en) * 1980-05-13 1984-02-14 Novo Industri A/S Method of producing an egg white substitute material
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5393668A (en) * 1991-09-11 1995-02-28 Hans-Wilhelm Doerr Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface
US5441868A (en) * 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5811299A (en) * 1994-02-08 1998-09-22 Renner; Wolfgang A. Methods for the activation of proliferation of animal cells
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US20030203448A1 (en) * 1999-09-28 2003-10-30 Manfred Reiter Medium for the protein-free and serum-free cultivation of cells

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT165999B (de) 1947-06-26 1950-05-25 Delle Atel Const Electr Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom
FR2196386A1 (en) * 1972-08-17 1974-03-15 Cudennec Alain Culture media selection - for identification of unknown bacteria
AU559856B2 (en) 1982-10-02 1987-03-19 Anderson Group Plc Line pans
JPS59187511A (ja) 1983-04-06 1984-10-24 株式会社日本バノツク 自動結束機
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
AU580145B2 (en) 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
DE3787805T2 (de) 1986-08-04 1994-02-10 Garvan Inst Med Res Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
KR890701731A (ko) 1987-06-30 1989-12-21 로버트 디. 웨이스트 칼리크레인의 제조방법
JP2507882B2 (ja) 1988-02-17 1996-06-19 工業技術院長 外部増殖因子非依存性増殖良好細胞株の製造法
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
JPH0789954B2 (ja) 1990-01-22 1995-10-04 アメリカ合衆国 細胞の保存と増殖のための二酸化炭素―非依存性増殖培地
JP2844484B2 (ja) 1990-02-22 1999-01-06 味の素株式会社 組換え蛋白質の生産方法
JP2859679B2 (ja) 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
JP2696001B2 (ja) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 組換え蛋白質産生用培地
AU643077B2 (en) 1990-10-19 1993-11-04 Unilever Plc Detergent compositions
JPH04228066A (ja) 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
JPH05123178A (ja) 1991-11-01 1993-05-21 Ajinomoto Co Inc Ｌ−フエニルアラニンの製造法
JPH06217759A (ja) 1993-01-25 1994-08-09 Sapporo Breweries Ltd 酵母プロトプラストの再生用培地と再生方法
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
AU7895898A (en) 1993-04-26 1998-10-08 Hans Wolf Mammal cell lines and method of obtaining glycoproteins
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
JP2766165B2 (ja) 1993-08-02 1998-06-18 株式会社バイオポリマー・リサーチ バクテリアセルロースの製造方法
EP0733100A1 (fr) 1994-09-09 1996-09-25 Wolfgang A. Renner Procede chimique favorisant la proliferation de cellules animales
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
ATE429246T1 (de) 1994-11-10 2009-05-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0799310A1 (fr) 1994-12-16 1997-10-08 Novartis AG Protection d'un constituant secretoire recombine
CA2211630A1 (fr) 1995-02-23 1996-08-29 Quest International B.V. Peptides destines a des milieux de culture tissulaire et cellulaire
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
EP2243827B2 (fr) 1996-08-30 2017-11-22 Life Technologies Corporation Milieu de culture de cellules de mammiferes exempt de serum
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
JP4543402B2 (ja) * 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション 植物由来栄養素を含む動物細胞培養培地
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
EP2267113B1 (fr) 1997-05-28 2013-07-17 Novartis AG Milieu de culture pour Neisseria meningitidis avec extrait de soja en tant que source d'acides aminés et dépourvu de complexes protéiques d'origine animale
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
FR2775983B1 (fr) 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
WO1999057246A1 (fr) 1998-05-01 1999-11-11 Life Technologies, Inc. Milieux de culture de cellules animales comprenant des elements nutritifs derives des vegetaux
EP0965583A1 (fr) * 1998-06-15 1999-12-22 Transgene S.A. Composés de polyamine et compositions les contenant, utiles pour le transfert de substances actives dans des cellules
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
PT1200561E (pt) * 1999-08-05 2006-09-29 Baxter Ag Clone celular recombinante estavel, sua producao e utilizacao
EP1210411B1 (fr) 1999-08-25 2006-10-18 Immunex Corporation Compositions et procedes permettant une culture cellulaire amelioree
KR100369788B1 (ko) 1999-09-03 2003-01-29 동아제약 주식회사 재조합 인간 에리트로포이에틴의 제조방법
NZ521732A (en) * 2000-03-22 2004-05-28 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines and factor VIII muteins
DE10015688A1 (de) 2000-03-29 2001-10-18 Siemens Ag Verfahren und Vorrichtung zum Zünden mindestens eines Zündelements für ein Rückhaltemittel in einem Kraftfahrzeug
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
WO2002024876A2 (fr) * 2000-09-25 2002-03-28 Polymun Scientific Immunbiologische Forschung Gmbh Vaccin vivant et procede de preparation
EP1208966A1 (fr) 2000-11-27 2002-05-29 Cheng-Kun Liao Procédé de fabrication d'une table de terrasse en verre de sécurité
DE10059175A1 (de) 2000-11-29 2002-06-20 Siemens Ag Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem
ES2291534T3 (es) 2001-10-02 2008-03-01 Novo Nordisk Health Care Ag Metodo para la produccion de proteinas recombinantes en celulas eucariotas.
CN101058800B (zh) * 2002-07-09 2013-03-13 巴克斯特国际有限公司 用于细胞培养的无动物蛋白质培养基
US20060281820A1 (en) * 2003-02-19 2006-12-14 Kuniyasu Soda Lfa-1 inhibitors and use thereof
KR20040088169A (ko) * 2003-04-09 2004-10-16 주식회사 제일생명공학서비스 동물세포 배양용 무혈청 배지
ES2565077T3 (es) 2003-10-10 2016-03-31 Novo Nordisk Health Care Ag Método para producción en gran escala de un polipéptido en células eucariotas
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
US4431629A (en) * 1980-05-13 1984-02-14 Novo Industri A/S Method of producing an egg white substitute material
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5441868A (en) * 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5633162A (en) * 1990-10-17 1997-05-27 Glaxo Wellcome Inc. Method for culturing Chinese hamster ovary cells
US5393668A (en) * 1991-09-11 1995-02-28 Hans-Wilhelm Doerr Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5811299A (en) * 1994-02-08 1998-09-22 Renner; Wolfgang A. Methods for the activation of proliferation of animal cells
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5885835A (en) * 1995-02-23 1999-03-23 Quest International Flavors & Food Ingredients Co., Division Of Indopco, Inc. Kit for in vitro cell growth of eucaryotes using low molecular weight peptides containing L-glutamine
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US20020182679A1 (en) * 1997-06-20 2002-12-05 Baxter Healthcare Corporation Recombinant cell clones having increased stability and methods of making and using the same
US6936441B2 (en) * 1997-06-20 2005-08-30 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US7094574B2 (en) * 1997-06-20 2006-08-22 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US20030203448A1 (en) * 1999-09-28 2003-10-30 Manfred Reiter Medium for the protein-free and serum-free cultivation of cells

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415133B2 (en) 2006-06-20 2013-04-09 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US20100008953A1 (en) * 2006-06-20 2010-01-14 Daniel Malarme Process for producing poxviruses and poxvirus compositions
US9295702B2 (en) 2006-06-20 2016-03-29 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US8945581B2 (en) 2006-06-20 2015-02-03 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US8058049B2 (en) 2006-06-20 2011-11-15 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US8415134B1 (en) 2006-06-20 2013-04-09 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US20100285533A1 (en) * 2008-01-09 2010-11-11 Krueger Olaf Culture media additive and process for using it
US8637312B2 (en) * 2008-01-09 2014-01-28 Cellca Gmbh Mammalian culture media with polyamine and iron
US9458422B2 (en) * 2008-01-25 2016-10-04 University Of Maryland Composition of matter and method for stimulating the growth of beneficial microorganisms
US20110053224A1 (en) * 2008-01-25 2011-03-03 Yangming Martin Lo Novel composition of matter and method for stimulating the growth of beneficial microorganisms
US8716016B2 (en) 2008-04-23 2014-05-06 Board Of Trustees Of Michigan State University Immortal avian cell line and methods of use
WO2009132195A1 (fr) * 2008-04-23 2009-10-29 Michigan State University Lignée cellulaire aviaire immortelle et procédés d’utilisation
US9441207B2 (en) 2008-06-16 2016-09-13 Intervet Inc. Method of replicating viruses in suspension cultures of dog kidney cells
WO2010056584A1 (fr) 2008-11-12 2010-05-20 Baxter International Inc. Procédé de production de facteur vii sans insuline, sans sérum
EP2977461A1 (fr) 2008-11-12 2016-01-27 Baxalta Incorporated Procédé de production de facteur vii exempt d'insuline et de sérum
US20100120093A1 (en) * 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
US11970724B2 (en) 2013-03-15 2024-04-30 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
CN109790521A (zh) * 2016-09-21 2019-05-21 德国癌症研究中心 在基本上无血清的培养基中大规模产生细小病毒h-1的优化的方法
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
CN110914293A (zh) * 2017-07-06 2020-03-24 里珍纳龙药品有限公司 用于制备糖蛋白的细胞培养工艺
US10905746B2 (en) 2017-07-07 2021-02-02 Baxalta GmbH Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
WO2019010496A1 (fr) 2017-07-07 2019-01-10 Baxalta Incorporated Traitement de patients atteints d'une forme grave de la maladie de von willebrand subissant une intervention chirurgicale non urgente par l'administration de vwf recombiné
US11529395B2 (en) 2017-07-07 2022-12-20 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
WO2019010497A1 (fr) 2017-07-07 2019-01-10 Baxalta Incorporated Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombiné
US12016904B2 (en) 2017-07-07 2024-06-25 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US10934340B2 (en) 2018-03-21 2021-03-02 Baxalta Incorporated Separation of VWF and VWF propeptide by chromatographic methods
WO2019183290A1 (fr) 2018-03-21 2019-09-26 Baxalta Incorporated Séparation de vwf et de propeptide de vwf par des procédés chromatographiques
WO2020160460A1 (fr) 2019-02-01 2020-08-06 Baxalta Incorporated Procédés de traitement prophylactique utilisant vwf recombinant (rvwf)
WO2021158777A1 (fr) 2020-02-04 2021-08-12 Baxalta Incorporated Traitement de la ménorragie chez des patients atteints de maladie de von willebrand sévère par administration de vwf recombinant

Also Published As

Publication number Publication date
DK2213724T3 (da) 2012-10-15
US20080009040A1 (en) 2008-01-10
WO2006045438A1 (fr) 2006-05-04
US9809796B2 (en) 2017-11-07
EP2213724B1 (fr) 2012-09-26
US20170267969A1 (en) 2017-09-21
EP2213725B1 (fr) 2012-08-22
US20110081680A1 (en) 2011-04-07
EP2213724A1 (fr) 2010-08-04
KR20070073930A (ko) 2007-07-10
RU2007119719A (ru) 2008-12-10
US20160083689A1 (en) 2016-03-24
US10138461B2 (en) 2018-11-27
AU2005299040B2 (en) 2011-07-07
PL2213725T5 (pl) 2024-05-13
EP2213725B2 (fr) 2024-02-14
EP2213725A1 (fr) 2010-08-04
FI2213725T4 (fi) 2024-04-29
PT2213725E (pt) 2012-09-24
EP2213726B1 (fr) 2012-12-05
MX2007005132A (es) 2007-07-04
KR101043547B1 (ko) 2011-06-21
PT2218776E (pt) 2012-09-24
CN101065480A (zh) 2007-10-31
SI2213724T1 (sl) 2012-11-30
US10655099B2 (en) 2020-05-19
PL2213726T3 (pl) 2013-04-30
EP2218776A1 (fr) 2010-08-18
HK1147110A1 (en) 2011-07-29
SI2213725T1 (sl) 2012-10-30
US20180023048A1 (en) 2018-01-25
EP2213724B2 (fr) 2023-12-27
US20110081722A1 (en) 2011-04-07
PT2213726E (pt) 2013-01-22
DK2213725T4 (da) 2024-04-15
DK2218776T3 (da) 2012-10-15
US9222075B2 (en) 2015-12-29
US9714411B2 (en) 2017-07-25
HK1147284A1 (en) 2011-08-05
DK2213725T3 (da) 2012-09-24
EP2213726A1 (fr) 2010-08-04
CA2585518A1 (fr) 2006-05-04
PL2218776T3 (pl) 2013-01-31
AU2005299040A1 (en) 2006-05-04
PT2213724E (pt) 2012-10-09
ES2393703T3 (es) 2012-12-27
PL2213725T3 (pl) 2013-01-31
US8748156B2 (en) 2014-06-10
ES2400214T3 (es) 2013-04-08
RU2383616C2 (ru) 2010-03-10
US20080064105A1 (en) 2008-03-13
JP2008517610A (ja) 2008-05-29
ES2393317T3 (es) 2012-12-20
PL2213724T3 (pl) 2013-02-28
US20130230919A1 (en) 2013-09-05
SI2218776T1 (sl) 2012-10-30
JP4847962B2 (ja) 2011-12-28
ES2394746T3 (es) 2013-02-05
US20150104867A1 (en) 2015-04-16
US8440408B2 (en) 2013-05-14
EP1805298A1 (fr) 2007-07-11
US20190078051A1 (en) 2019-03-14
US20080064080A1 (en) 2008-03-13
EP2218776B1 (fr) 2012-08-29
CN101065480B (zh) 2010-05-26
DK2213726T3 (da) 2013-01-21

Similar Documents

Publication Publication Date Title
US10655099B2 (en) Animal protein-free media for cultivation of cells
US9758568B2 (en) Oligopeptide-free cell culture media
AU2011221414B2 (en) Animal Protein-Free Media for Cultivation of Cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;REEL/FRAME:016184/0507;SIGNING DATES FROM 20050329 TO 20050413

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;REEL/FRAME:016184/0507;SIGNING DATES FROM 20050329 TO 20050413

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION